title: Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).
abstract: Treatment for primary and secondary immunodeficiency disorders focuses on prevention and management of infections, using immunoglobulin G (IgG) replacement therapy with regular intravenous or subcutaneous IgG (SCIG) infusions. SCIG therapy has many advantages including improved efficacy and tolerability, enhanced patient satisfaction and lower costs. A number of SCIG preparations are available, including Gammanorm(®) (Octapharma AG), a ready-to-use 16.5% liquid preparation of IgG, with low viscosity, well suited to self-administration and a long history of use. Clinical experience with Gammanorm has shown that it is effective and well tolerated in children and adults, including pregnant women, for primary and secondary immunodeficiency disorders. Recent data also suggest SCIG may have a role in the treatment of certain immune-mediated conditions.
authors.affiliation: The Unit for Clinical Nursing Research & Clinical Research in Immunotherapy, Division of Clinical Immunology, Department of Laboratory Medicine and Transfusion Medicine, Karolinska Institutet, SE-141 83 Huddinge, Stockholm, Sweden.|The Japanese Red Cross Institute for Humanitarian Studies, Tokyo, Japan.
authors.forename: Ann
authors.initials: A
authors.lastname: Gardulf
mesh_terms: D061605:Administration, Intravenous; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000276:immunology / Q000628:therapy*; D007279:Injections, Subcutaneous; D017060:Patient Satisfaction; D011247:Pregnancy
chemical_list: D016756:Immunoglobulins, Intravenous
keywords: Gammanorm®; efficacy; immunoglobulin; primary immunodeficiency disorders; quality of life; subcutaneous; tolerability